Changes in etanercept and adalimumab biosimilar prescriptions for the initial treatment of rheumatoid arthritis in France: Data from the ART-SFR Registry

Joint Bone Spine. 2022 May;89(3):105310. doi: 10.1016/j.jbspin.2021.105310. Epub 2021 Nov 25.
No abstract available

Keywords: Anti-TNF; Biosimilar; Rheumatoid arthritis.

Publication types

  • Letter

MeSH terms

  • Adalimumab / therapeutic use
  • Antirheumatic Agents* / therapeutic use
  • Arthritis, Rheumatoid* / diagnosis
  • Arthritis, Rheumatoid* / drug therapy
  • Arthritis, Rheumatoid* / epidemiology
  • Biosimilar Pharmaceuticals* / adverse effects
  • Etanercept / adverse effects
  • Humans
  • Infliximab / therapeutic use
  • Prescriptions
  • Registries
  • Tumor Necrosis Factor-alpha / therapeutic use

Substances

  • Antirheumatic Agents
  • Biosimilar Pharmaceuticals
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab
  • Etanercept